MedTrace Logo

Mechanism of Serum PRL in the Development of MAFLD

NCT05525884 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-09-02

No results posted yet for this study

Summary

Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently. However, the relationship between serum PRL and MAFLD among diabetic patients is unclear. The investigators aimed to explore the association between serum PRL and the risk of MAFLD in patients with type 2 diabetes (T2DM).

Conditions

  • Type2 Diabetes
  • Fatty Liver, Nonalcoholic
  • Liver Fibrosis

Interventions

OTHER

non-invasive method, Fibroscan

Liver Ultrasound and transient elastography (FibroScan®)

Sponsors & Collaborators

  • Shen Qu

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2024-01-01
Completion
2024-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05525884 on ClinicalTrials.gov